I find it interesting that there was no mention of insurance coverage for this new drug or the other high priced drugs such as Harvoni. If it takes months of arguing with the insurance companies to provide the drug what has happened to the spread of these diseases (leukemia or hepatitis c in the case of Harvoni) during this period?<p>Worse, are we developing drugs that are only available to the wealthiest people? As a former government employee, I am always suspect of claims such as:<p>>the Switzerland-based company defended the cost by announcing a relatively new approach to pricing: If the drug doesn’t work after the first month, patients pay nothing.<p>Who determines whether the drug is working? Is there a minimal level of "working" that must be met in order to "pay nothing?" These are the questions that will cause the insurance companies to take even longer to approve payment of Kymriah.<p>Plus I loved the if it isn't working the patient doesn't pay? When the insurance companies refuse to cover this drug, a patient will only get it by "paying." Then it will be, good luck getting your money back if it is not working and again, will the measuring stick for the determination of working be always moving.<p>Plus, as an aside, I see Harvoni commercials quite often on TV and in magazines. Maybe if we in the US did not allow big Pharma to advertise just like many other countries then a single dose of Harvoni would not cost "$87,000 and rising."